Prostate Cancer News Archive
Statin use is associated with greater overall survival among men with metastatic castration-resistant prostate cancer and improved survival among patients with high-risk prostate cancer.
In a study, a negative confirmatory prostate biopsy in prostate cancer patients on active surveillance predicts a lower risk of progressing to treatment.
In separate studies, apalutamide and enzalutamide prolonged metastasis-free survival in men with non-metastatic castration-resistant prostate cancer.
In a study of hypogonadal men, those who received testosterone therapy had a lower incidence of prostate cancer than those who did not.
The technology facilitates teaching of advanced surgical skills, delivery of care to underserved
The investigators observed no difference in mortality between BT alone and BT plus ADT and/or EBRT supplemental therapy.
In a study, the 17-year prostate cancer-specific and biochemical failure-free survival rates were 97% and 79%, respectively.
Adjuvant radiotherapy was associated with lower risks for biochemical failure and distant metastases and increased overall survival in patients with adverse pathologic features found after radical prostatectomy.
Following radical prostatectomy, higher BMI increases risk of recurrence for prostate cancer.
Androgen-deprivation therapy without estrogen is associated with a significant 43% increased risk of thromboembolic events, meta-analysis shows.
In a meta-analysis, the risk of infectious complications was 78% lower with fosfomycin trometamol versus fluoroquinolones in men undergoing TRUS-guided prostate biopsy.
In a single center study, asymptomatic bacteriuria resolved before prostate biopsy, without additional treatment.
Polygenic hazard score can guide screening based off predicted prostate cancer diagnosis age.
A study showed longer survival among patients with metastatic hormone-sensitive prostate cancer who achieved a PSA level of 0.2 ng/mL or less 7 months after initiating ADT.
Study finds that closely adhering to a Mediterranean-style diet possibly protects men from aggressive and advanced prostate cancer.
Each 10 mg/dL increase in serum levels of total and HDL cholesterol are associated with a significant 5% and 14% increased risk of high-grade PCa, respectively.
Patient age 70 years and above is an independent risk factor for perioperative morbidity, according to data from a national cohort.
Patients who have to travel longer distances for prostate cancer treatment are more likely to receive stereotactic body radiotherapy.
Rates of erectile dysfunction and urinary incontinence at 1, 2, and 3 years after radical surgery are not higher among men who have multiple prostate biopsies while on active surveillance for prostate cancer.
A rotating shift schedule appeared the most risky.
Among patients with high-risk prostate cancer, investigators observe no significant difference in cancer-related death risk between radiotherapy and radical prostatectomy.
An analysis of an intervention arm of the PLCO Cancer Screening Trial evaluated the risk of prostate cancer relative to dietary consumption of isoflavones, a dietary compound found in some plant foods.
Male patients with mCRPC and seizure risk factors did not have increased seizure incidents when taking Enzalutamide.
Recent research suggests that P. acnes, which is associated with acne vulgaris, is more likely to be present in the prostatic tissue of patients with the disease than in healthy individuals.
A negative mpMRI is associated with a higher risk for PSA recurrence and metastasis following salvage radiotherapy for recurrent prostate cancer after radical prostatectomy.
Cancer survival was greatly skewed toward patients with Medicare or private insurance.
Investigators who compared 4 active surveillance cohorts found that biennial prostate biopsies appear to be an acceptable alternative to annual biopsies.
Results of a large prospective study show that appropriate use of the phi test can improve physicians' ability to diagnose and manage patients.
Assessments of androgen receptor, glycolysis prognostic in castration-resistant prostate cancer.
Hypogonadal men who received testosterone replacement therapy had a lower incidence of prostate cancer than those who did not, and their cancers were less severe.
In a prospective study, mCRPC patients placed on enzalutamide after their disease progressed while on abiraterone therapy had a median radiographic progression-free survival of 8.1 months.
In a small but meaningful number of patients, Gleason pattern 4 disease missed by MRI and systematic biopsy is present outside the focal ablation zone.
The variant HSD3B1 allele increases the likelihood of metastasis in men receiving androgen-deprivation therapy for biochemically recurrent disease after radiotherapy for localized PCa.
Non-metastatic prostate cancer patients are more likely to die from causes other than the disease.
Exposure to androgen-deprivation therapy was associated with a nearly 2-fold increased risk of heart failure among men without pre-existing cardiovascular disease.
Biochemical failure and prostate cancer-specific mortality rates were 13.3% and 4.9% at 10 years, respectively.
Pathologic stages T3a and T3b versus T2a were associated with 8.45 and 7.1 times increased risk of biochemical recurrence on multivariable analysis.
The later a man's testosterone level dropped below 12.1 nmol/L, the lower his lifetime risk for prostate cancer.
Researchers find BRCA2 mutations are associated with worse outcomes among men with mCRPC.
Use of intensity-modulated radiation therapy for prostate cancer increased from 3.5% to 64% from 2002 to 2012.
In a case-control study, men who had ever used non-steroid anti-inflammatory drugs had a 23% decreased risk of prostate cancer.
Use of active surveillance for very low-risk prostate cancer rose from 11.6% of patients in 2010 to 27.3% in 2013, study finds.
Following curative treatment for localized PCa, 5-year PCa-specific survival rates are higher for patients with initial lymph node or locoregional metastases versus initial metastases in bone only or in multiple sites.
Findings from this comparative study indicate a favorable failure-free survival and progression-free survival with Standard of Care plus abiraterone acetate and prednisone.
PSA levels of 10 ng/mL or higher in men who have biochemically recurrent PCa after radical prostatectomy and a PSADT less than 12 months are at imminent risk for metastatic disease.
The researchers found that there was no difference between the 6- and 2-fraction groups in baseline and post-implantation IPSS scores.
A European trial found a survival benefit from PCa screening and a US trial did not, but a new analysis finds that both trials provide compatible evidence that screening decreases PCa mortality.
In a study, the risk for heart failure was 81% higher among patients who received androgen deprivation therapy.
Patients are more likely to receive intensity-modulated radiation therapy if they are managed by urology practices with an ownership interest in the modality, study finds.
The six-month cumulative incidence of myocardial infarction was 2.0% and 0.7% in patients with cancer and controls, respectively.
Prostate cancer patients accurately report their comorbidities, and participants in cancer clinical trials report more adverse events than trial investigators.
Improvement in BMD was seen with denosumab, which also reduced the incidence of new radiographic vertebral fractures in one high-quality trial.
Men with 1 high-risk factor experience better outcomes following treatment than those with 2 or 3 high-risk factors, study finds.
Study of men with intermediate- or high-risk prostate cancer finds facility-level racial disparity in use of definitive treatment.
A detectable PSA nadir combined with shorter time to nadir after prostate cancer surgery is associated with a higher risk of biochemical recurrence.
63% of patients were managed initially with observation.
Nearly 1 in 3 patients diagnosed with Gleason 3+4 favorable intermediate-risk prostate cancer had their disease upgraded or upstaged at radical prostatectomy.
Most common infection in prostate biopsy was E. coli, followed by mild bleeding.
Throughout the study, a total of 115 lobes were treated and 82% achieved absent clinically significant cancer.
Researchers calculated that the absolute increase in lifetime risk of prostate cancer associated with vasectomy was just 0.6%.
Study reveals that a quarter of men with low-volume intermediate-risk prostate cancer had adverse pathologic features found at radical prostatectomy.
Every additional 4 inches of height was associated with a 21% increase in risk of being diagnosed with high-grade prostate cancer, and a 17% increased risk of dying from prostate cancer.
Randomized trial found no significant difference in all-cause and cancer-specific survival between radical prostatectomy and observation for localized prostate cancer.
Across time, only African-American race correlated with greater regret.
Men with prostate cancer and at least one additional primary cancer are enriched for harboring a germline deleterious mutation in a cancer-predisposing gene.
Over a 10-year period, radical prostatectomy use increased steadily while radiotherapy use declined
Both findings on biopsy also predict a lower odds of high-grade cancer.
Prostate cancer patients on active surveillance who have no cancer found on confirmatory biopsy have a reduced risk of grade and volume reclassification.
Over 15 years of follow-up, considerable proportion of men undergo prostate-specific antigen testing
No added benefit was seen with the addition of biomarkers for African-American men.
New findings suggest that clinicians consider the pathologic characteristics of the primary tumor as well as the burden of LN metastases when deciding on management, investigators say.
Radiotherapy for prostate cancer patients with persistently elevated PSA after radical surgery improved survival only among those with worse pathologic characteristics.
High-income counties had far higher diagnosis rates for the four cancers than low-income counties, but the combined mortality rate was similar for both.
The researchers found that the median overall survival was 31.2 and 26.0 months in the PRO and usual care groups, respectively.
Some men who undergo multigene testing for inherited prostate cancer misinterpret findings of variants of uncertain significance.
Younger patients who chose surgery vs radiation for initial treatment had a 48% survival advantage.
Extended pelvic lymph node dissection versus limited dissection during radical prostatectomy does not improve biochemical recurrence rates.
CBP was associated with a reduction in sperm concentration, sperm vitality, sperm total and progressive motility.
New findings establish single-dose radiotherapy as the standard of care for metastatic spinal canal compression, at least for patients with a short life expectancy, researcher says.
ECOG status and baseline PSA and PSADT are significantly associated with overall survival.
Men with PSA values of 2.5 ng/mL or less and Gleason 8 to 10 prostate tumors are at higher risk of death than other high-risk PCa patients.
The researchers found that predicted monthly costs remained relatively stable throughout the observation period among the controls.
Addition of abiraterone to androgen deprivation therapy for patients with hormone-naïve advanced prostate cancer may be a new standard of care.
The 3-year overall survival rate among prostate cancer patients starting long-term hormone therapy was 83% vs 76% for men receiving abiraterone plus ADT vs ADT alone.
Urinary incontinence and diminished sexual function were common after a median follow-up of nearly 15 years, study finds.
Overall complication rates were similar between primary and salvage RARP groups, but there were some notable differences in prognosis.
Systematic biopsies always should be performed in conjunction with targeted biopsy in men with suspected clinically significant PCa at mpMRI.
The new test, IsoPSA, measures all PSA isoforms in serum and more accurately discriminates high-grade cancer from benign disease.
Combining testing of urinary T2:ERG, PCA3 at thresholds that detected aggressive prostate cancer improved specificity from 18% to 39%.
The investigators found that the percentage of patients diagnosed with stage I cancer increased significantly from 2013 to 2014 after the ACA was implemented.
Only luminal B prostate cancers were significantly associated with postoperative response to ADT in a subset analysis in retrospective cohorts.
A majority of active surveillance patients under age 60 did not progress to definitive prostate cancer treatment.
Targeting PI-RADS 4 and 5 lesions for confirmatory biopsy improves detection of clinically significant cancer.
Median overall survival was 9.3 months longer for black versus white patients with metastatic castration-resistant prostate cancer.
Fusion biopsy has improved over the last decade and increasingly detects clinically significant prostate cancer, according to data trends from one institution.
Highest quartile of alkaline phosphatase velocity in men who experience biochemical recurrence after radical prostatectomy is associated with 2-fold higher risk.
Systematic biopsy parameters identified patients at higher risk of positive surgical margins.
The laser procedure was successful for 7 selected patients with enlarged prostates and LUTS harboring low-risk prostate cancer.
The new risk models improve upon PI-RADS version 1.0 and ERPSC risk calculators used for prostate biopsy decisions.
Nomogram based on a cohort of men with high-risk prostate cancer is more accurate than the CAPRA and MSKCC nomograms, researchers report.
Renal and Urology News Articles
Sign Up for Free e-newsletters
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)